Kuros Biosurgery AG Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers
9/1/2011 7:18:56 AM
More...
|
Kuros Biosurgery AG Completes Patient Recruitment in its European Clinical Study With KUR-023, its Novel Dural Sealant Product Candidate
8/17/2011 5:55:23 AM
More...
|
Kuros Biosurgery AG Announces Allowance of US Patent for the Local Application of Parathyroid Hormone (PTH) for Bone Healing
7/19/2011 6:23:26 AM
More...
|
Kuros Biosurgery AG Announces Allowance of European Patent for Synthetic Biomaterials
6/20/2011 6:45:31 AM
More...
|
Kuros Biosurgery AG Completes Patient Recruitment In A Phase Iib Trial Of Kur-111 In Patients With Tibial Plateau Fractures
6/8/2009 2:05:45 PM
More...
|
Kuros Biosurgery AG Announces Grant Of United States Patent For Synthetic Biomaterials
10/13/2008 2:17:03 PM
More...
|
Kuros Biosurgery AG and Aeris Therapeutics, Inc. Announce Exclusive License Agreement in the Field of Lung Volume Reduction
9/23/2008 6:48:19 AM
More...
|
Kuros Biosurgery AG Announces Results Of ONE-Month Follow-Up Of Phase IIa Trial of KUR-212 in Patients with Burns requiring Mesh Grafting; KUR-212 Meets Phase IIa Trial Primary Endpoint
8/11/2008 11:51:36 AM
More...
|
Kuros Biosurgery AG Appoints Beat Neukom as its Chief Financial Officer
7/7/2008 12:36:10 PM
More...
|
Kuros Biosurgery AG Starts Phase IIb Clinical Trial With Kur-113 In Open Tibial Fractures
6/10/2008 9:28:39 AM
More...
|
|